Addex Therapeutics (ADXN) Financial Statements & Analysis

Addex Therapeutics (ADXN) Income Statement

Addex Therapeutics reported revenue of CHF 172.86K in fiscal 2025 (fiscal year ended Dec 31, 2025), down 57.2% from CHF 404.10K a year earlier. Addex Therapeutics posted a net loss of CHF 6.73M, compared with net income of CHF 7.06M a year earlier. Gross margin was 100.0% and operating margin -1628.3%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was CHF 9.95K, down 72.7% from the same quarter a year earlier.

Addex Therapeutics Income Statement Analysis

Values in millions CHF

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Addex Therapeutics Ltd income statement - Annual data in millions CHF
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Mar 2025	Dec 2024	Mar 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Mar 2020	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	0.17	0.40	0.41	1.61	1.61	1.44	2.92	3.88	2.76	6.04	0.50
Cost of Revenue	0.67	0.00	0.85	0.00	1.19	8.23	0.00	10.37	0.23	0.14	0.03
Gross Profit	0.17	0.40	0.41	1.61	1.62	1.44	2.92	-6.49	2.53	5.90	0.47
Operating Expenses
Research & Development	0.67	0.44	0.85	0.94	0.94	8.24	9.01	10.37	12.45	2.37	0.84
Selling, General & Administrative	2.32	1.68	2.31	2.03	2.03	3.76	7.75	5.75	4.31	4.72	2.20
Operating Expenses	2.99	3.16	3.17	3.86	3.86	11.99	18.42	5.75	17.14	7.47	3.24
Operating Income	-2.81	-2.76	-2.76	-2.24	-2.24	-10.54	-15.51	-12.24	-14.60	-1.42	-3.24
Other Income/Expense
Interest Income	0.00	0.01	0.03	0.06	0.06	0.03	0.01	0.04	0.04	0.09	0.00
Interest Expense	0.00	0.00	0.00	0.02	0.00	-0.03	0.06	-0.07	0.13	0.22	0.05
Other Income/Expense	-4.03	-2.15	-2.15	-0.26	-0.32	-0.26	0.15	-0.62	-0.18	-0.22	-0.05
Income
Income Before Tax	-6.84	-4.91	-4.91	-2.50	-2.50	-10.80	-15.35	-12.86	-14.78	-1.64	-3.28
Income Tax Expense	0.00	0.00	-	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-6.73	7.06	7.06	-10.56	-10.56	-20.80	-15.35	-12.86	-14.78	-1.64	-3.28
Net Income - Continuous Operations	-6.84	7.06	-4.91	-10.56	-2.50	-10.80	-15.35	-12.86	-14.78	-1.64	-3.28
Net Income - Discontinued Operations	0.11	-	11.97	-	-8.06	-10.00	-	-	-	-	-
EBITDA	-2.81	-4.65	-2.56	-2.19	-2.19	-10.53	-14.94	-11.86	-14.32	-1.51	-3.22
EBIT	-2.81	-	-2.76	-	-2.50	-10.54	-15.51	-12.24	-	-	-
Depreciation & Amortization	0.01	0.26	0.19	0.31	0.01	0.01	0.35	0.38	0.33	0.00	0.02
Earnings Per Share
Basic EPS	-	8.00	-	-17.00	-17.00	-	-54.00	-58.00	-67.00	-8.00	-30.00
Diluted EPS	-7.00	8.00	8.00	-17.00	-17.00	-55.00	-54.00	-	-67.00	-8.00	-30.00
Basic Shares Outstanding	107.37	0.82	98.11	0.62	0.62	45.18	0.28	0.22	0.22	0.19	0.11
Diluted Shares Outstanding	107.37	0.82	98.11	0.62	0.62	45.18	0.28	0.22	0.22	0.19	0.11

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Addex Therapeutics Financial Statements

What was Addex Therapeutics's revenue in fiscal 2025?

Addex Therapeutics reported revenue of CHF 172.86K in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 57.2% from CHF 404.10K a year earlier.

Is Addex Therapeutics profitable?

No. Addex Therapeutics reported a net loss of CHF 6.73M in fiscal 2025. In fiscal 2024 it earned CHF 7.06M.

What is Addex Therapeutics's operating margin?

Addex Therapeutics's operating income was −CHF 2.81M on revenue of CHF 172.86K in fiscal 2025, an operating margin of -1628.3%, compared with -681.8% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition